Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2von Hippel-Lindau Disease 1Triple Negative Breast Neoplasms 1Sarcoma, Kaposi 1Sarcoma 1Neoplasm Metastasis 1Metastatic Digestive System Neuroendocrine Tumor G1 1Meningioma 1Liposarcoma 1Leiomyosarcoma 1Hamartoma Syndrome, Multiple 1Glioma 1Glioblastoma 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Renal Cell 1Brain Neoplasms 1Bone Neoplasms 1Autistic Disorder 1Astrocytoma 1

Interventions

Letrozole 25Fulvestrant 25Specimen Handling 19ribociclib 16Capecitabine 16pembrolizumab 14palbociclib 14Paclitaxel 14Trastuzumab 13Carboplatin 13exemestane 12abemaciclib 12Tamoxifen 12Anastrozole 12Magnetic Resonance Spectroscopy 11trastuzumab deruxtecan 8pertuzumab 8Biopsy 8Goserelin 7inavolisib 6giredestrant 6Cyclophosphamide 6130-nm albumin-bound paclitaxel 6patritumab deruxtecan 5eribulin 5elacestrant 5Taxes 5Standard of Care 5Radiotherapy 5Gonadotropin-Releasing Hormone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × Everolimus × 30 days × Clear all
NCT07340541 2026-05-20

EVOLVE-BDT

UNC Lineberger Comprehensive Cancer Center

Phase 2 Recruiting
700 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06428396 2026-05-18

LITESPARK-029

Merck Sharp & Dohme LLC

Phase 2 Recruiting
120 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡